An observational study in Melanoma, sponsored by Bristol-Myers Squibb. Withdrawn at 1 site in United States. Open to female participants. Per ClinicalTrials.gov, last updated 2022-03-31.
Sponsored by Bristol-Myers Squibb · Observational
The study is a global safety surveillance study of pregnancy outcomes in women who were exposed to ipilimumab during pregnancy and pediatric outcomes up to 5 years of age
3,006 studies on the registry are indexed under Melanoma; 519 are open to participants now.
Browse Melanoma studies →Bristol-Myers Squibb is the lead sponsor of 1,538 studies on the registry; 116 are open to participants now.
Of its 429 completed or terminated interventional studies of FDA-regulated products, 223 (52%) have results posted.
Counted across the registry records on this site, refreshed daily.
Primary Care Clinic
Exclusion Criteria:
Other protocol defined inclusion/exclusion criteria could apply
Women Exposed to Yervoy (ipilimumab) During Pregnancy and the Children from These Pregnancies
Drug: Yervoy
Also known as: ipilimumab
Incidence of structural birth defects in infants born to mothers exposed to Yervoy while pregnant
Time frame: Birth up to 12 months
Incidence of chromosomal birth defects in infants born to mothers exposed to Yervoy while pregnant
Time frame: Birth up to 12 months
Delays in developmental milestones
Time frame: Birth up to 5 Years
Clinical Signs of Immune or Endocrine Dysfunction
Time frame: Birth up to 5 Years
Clinical Signs of Autoimmune Disorders
Time frame: Birth up to 5 Years
Clinical Signs of Serious Infections and Malignancy
Time frame: Birth up to 5 Years
Adverse Pregnancy Outcomes
Elective or spontaneous abortion, fetal death/stillbirth, pre-term delivery, ectopic or molar pregnancy
Time frame: Time of Conception up to Birth
This study is withdrawn, as verified in Mar 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Bristol-Myers Squibb